NasdaqGS:MLYSBiotechs
Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires?
In March 2026, Mineralys Therapeutics appointed Jeffrey A. Munsie as Chief Legal Officer, bringing nearly 25 years of biopharma legal experience, including prior leadership roles at Orbital Therapeutics, Concert Pharmaceuticals and Merrimack Pharmaceuticals.
This hire adds seasoned expertise in intellectual property, compliance and transactions at a time when Mineralys is advancing lorundrostat through late-stage clinical development and regulatory review.
With Munsie’s deep biopharma legal...